文献速递血栓与止血

估算住院内科患者静脉血栓栓塞症预防风险阈值的决策模型

A decision model to estimate a risk threshold for venous thromboembolism prophylaxis in hospitalized medical patients.
PubMed 文献 · J Thromb Haemost · 2017-05-03

该研究构建决策树与终身马尔可夫模型,追踪住院内科患者3个月内及长期结局,估算静脉血栓栓塞症预防的风险阈值。在支付意愿阈值10万美元/质量调整生命年下,平均患者VTE风险≥1.0%时预防具有成本效果;出血风险>8.1%、年龄>73.4岁或依诺肝素费用>$60/剂时预防不推荐。决策应基于患者VTE风险、年龄和预期寿命个体化。

要点

  • 支付意愿阈值为10万美元/质量调整生命年时,平均内科住院患者VTE风险≥1.0%可考虑预防。
  • 出血风险>8.1%、年龄>73.4岁或依诺肝素费用>$60/剂时,平均患者不推荐预防。
  • VTE风险<0.26%或出血风险>19%时,预防的风险超过获益。

核心结论

  • 预防决策应基于患者VTE风险、年龄和预期寿命个体化。
  • 在支付意愿10万美元/质量调整生命年下,3个月VTE风险低于1.0%的多数患者不需要预防。

研究设计与样本

  • 构建决策树追踪患者住院后3个月,并构建3个月周期的终身马尔可夫模型。
  • 模型追踪症状性深静脉血栓、肺栓塞、出血事件和肝素诱导的血小板减少症;长期并发症包括复发性VTE、血栓后综合征和肺动脉高压。
  • 基础病例为66岁内科住院患者,预期寿命13.5年,VTE风险1.4%,出血风险2.7%。
  • 患者接受依诺肝素40 mg/天预防。

主要发现

  • 假设支付意愿阈值为10万美元/质量调整生命年,平均内科住院患者VTE风险≥1.0%时,住院后3个月内预防有指征。
  • 平均患者出血风险>8.1%、年龄>73.4岁或依诺肝素费用>$60/剂时,预防无指征。
  • VTE风险<0.26%或出血风险>19%时,预防的风险超过获益。
  • 预防阈值对低分子量肝素费用和出血风险相对不敏感,但对患者年龄和预期寿命非常敏感。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Low risk patients don't require venous thromboembolism (VTE) prophylaxis; low risk is unquantified. We used a Markov model to estimate the risk threshold for VTE prophylaxis in medical inpatients. Prophylaxis was cost-effective for an average medical patient with a VTE risk of ≥ 1.0%. VTE prophylaxis can be personalized based on patient risk and age/life expectancy. SUMMARY: Background Venous thromboembolism (VTE) is a common preventable condition in medical inpatients. Thromboprophylaxis is recommended for inpatients who are not at low risk of VTE, but no specific risk threshold for prophylaxis has been defined. Objective To determine a threshold for prophylaxis based on risk of VTE. Patients/Methods We constructed a decision model with a decision-tree following patients for 3 months after hospitalization, and a lifetime Markov model with 3-month cycles. The model tracked symptomatic deep vein thromboses and pulmonary emboli, bleeding events and heparin-induced thrombocytopenia. Long-term complications included recurrent VTE, post-thrombotic syndrome and pulmonary hypertension. For the base case, we considered medical inpatients aged 66 years, having a life expectancy of 13.5 years, VTE risk of 1.4% and bleeding risk of 2.7%. Patients received enoxaparin 40 mg day-1 for prophylaxis. Results Assuming a willingness-to-pay (WTP) threshold of $100 000/ quality-adjusted life year (QALY), prophylaxis was indicated for an average medical inpatient with a VTE risk of ≥ 1.0% up to 3 months after hospitalization. For the average patient, prophylaxis was not indicated when the bleeding risk was > 8.1%, the patient's age was > 73.4 years or the cost of enoxaparin exceeded $60/dose. If VTE risk was < 0.26% or bleeding risk was > 19%, the risks of prophylaxis outweighed benefits. The prophylaxis threshold was relatively insensitive to low-molecular-weight heparin cost and bleeding risk, but very sensitive to patient age and life expectancy. Conclusions The decision to offer prophylaxis should be personalized based on patient VTE risk, age and life expectancy. At a WTP of $100 000/QALY, prophylaxis is not warranted for most patients with a 3-month VTE risk below 1.0%.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Le P, Martinez KA, Pappas MA, et al. A decision model to estimate a risk threshold for venous thromboembolism prophylaxis in hospitalized medical patients. J Thromb Haemost. 2017. PMID: 28371250. doi:10.1111/jth.13687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。